Quick Takeaways: Why It Matters? BiomEdit’s USDA conditional licensure for CPerf LLV (to be branded Optavant) creates the first genetically engineered probiotic biologic for poultry, offering a non‑antibiotic tool against necrotic enteritis-a disease costing the global broiler ...
Quick Takeaways: Why It Matters? ECO Animal Health’s acceptance of field safety data for Ecovaxxin MS by the USDA‑CVB is a key regulatory step toward US licensure of its Mycoplasma synoviae poultry vaccine, following the product’s EU commercial launch in July 2026. The large fi...
Quick Takeaways: Why It Matters? Zoetis’ EC approval of Poulvac Procerta HVT-ND turns its single-dose, dual ND+Marek’s protection into a mainstream EU option, which should drive rapid adoption as producers shift from multi-vaccine schedules to a streamlined, in‑ovo or hatch-day protocol th...
Quick Takeaways: Why It Matters? ECO Animal Health’s EU launch of Ecovaxxin MS is a meaningful commercial milestone because it converts the company’s own R&D pipeline into a marketed product and gives it a differentiated position in poultry vaccines. With access to a market spanning mo...
Quick Takeaways: Why It Matters? The USDA’s positive safety verdict for Ecovaxxin MG significantly de‑risks US registration, validating ECO’s live‑strain platform and setting up a clear path toward a 2027 filing in a large Mycoplasma gallisepticum market.&nb...
